UNSPSC 51392502: Tretoquinol

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C19H23NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JIO3275WGI, chemically known as 6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-, hydrochloride, (s)- but generally known as tretoquinol, which bears US NIH Compound Identifier 29137. European Medicines Agency schedules Tretoquinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11248MIG.

UNSPSC 51392502 Tretoquinol is a Commodity code that covers pharmaceutical products and related medical supplies procured by state and local health agencies. The recent state and local solicitations under this code show activity in naloxone acquisition and broader pharmacy benefit program expansion rather than tretoquinol specifically. State health agencies and county health departments are the primary issuing bodies, seeking to purchase naloxone units, drug deactivation systems, and to establish direct-to-manufacturer prescription fulfillment capabilities as part of community health and pharmacy benefit initiatives. The work involves competitive procurement of pharmaceutical inventory with quarterly or ongoing delivery requirements, vendor qualification for federal compliance (E-Verify, drug-free workplace certification, FEMA-related regulations), and contract terms typically spanning two years with renewal options.

Recent activity centers in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with a response deadline of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring state capacity to establish direct relationships between pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Texas RFI represents early-stage market research preceding a formal RFP, while the Seminole County opportunity is an active competitive bid cycle.